Randomized Phase III Study Of Sorafenib Versus Stereotatic Body Radiation Therapy Followed By Sorafenib In Hepatocellular Carcinoma
Posted Date: May 15, 2019
- Investigator: Kevin Redmond
- Type of Study: Drug
The purpose of this study is to compare the effects of sorafenib alone (the present standard of care treatment) with SBRT followed by sorafenib on you and your liver cancer to find out which is better. In this study, you will get either SBRT followed by sorafenib or the sorafenib alone.
Criteria:
To Be Eligible For This Study, Patients Must Have Primary Liver Cancer, Referred To As Hepatocellula
Keywords:
Cancer, R1112, Gastrointestinal, Radiation, Liver Cancer
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu